Silica-Matrix Encapsulation for Biomaterial Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Biomaterials, such as enzymes and microorganisms, face challenges in immobilization due to instability and loss of catalytic activity when traditional encapsulation methods are used, leading to issues like denaturation and aggregation, especially in harsh conditions, which limits their practical application in biotechnology and medicine.
Innovation Solution
The development of silica-matrix encapsulation methods using reactive silicon compounds and organic precursors to form nanoporous or macroporous structures that retain the catalytic activity of biomaterials, allowing for their use in extended periods and harsh conditions without additional steps for byproduct removal.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional encapsulation materials are used to immobilize biomaterials, then the biomaterials can be retained at the application site, but the biomaterials lose catalytic activity due to denaturation and aggregation
Solution Approach 1:
The patent employs porous silica materials with controlled pore sizes (mesoporous 2-50 nm or macroporous 50-200 nm) to encapsulate biomaterials. The porous structure provides physical support while allowing small molecules to diffuse freely, preventing denaturation and aggregation of the biomaterials while maintaining their catalytic activity.
Solution Approach 2:
The patent creates composite encapsulation systems combining silica matrix with organic precursors or surfactants. These composite materials provide both the mechanical robustness needed for immobilization and the chemical environment necessary to preserve biomaterial stability and catalytic function.
2Reliability
If silica nanoparticles are used for microorganism immobilization, then the microorganisms can be retained, but proteins are adsorbed into the silica causing denaturation and loss of catalytic activity
Solution Approach 1:
The patent introduces organic precursors or surfactants as intermediary substances between the silica nanoparticles and the biomaterials. These intermediaries modify the silica surface properties, preventing direct protein-silica interactions that cause denaturation, while still allowing the silica to provide structural support for immobilization.
Solution Approach 2:
The patent modifies the surface chemistry parameters of silica nanoparticles by controlling pH, adding organic modifiers, or using different silica preparation methods. These parameter changes reduce the harmful adsorption effects on proteins while maintaining the immobilization capability.
3Ease of manufacture
If encapsulation procedures include hydrolysis or condensation steps, then the silica matrix can be formed, but additional steps are required to remove byproducts
Solution Approach 1:
The patent uses pre-synthesized porous silica materials or colloidal silica as ready-made encapsulation matrices, eliminating the need for in-situ hydrolysis and condensation steps. This extraction of the problematic chemical steps simplifies the overall process while maintaining effective encapsulation.
Solution Approach 2:
The patent prepares the silica matrix structure in advance through controlled synthesis methods that minimize byproduct formation. By performing preliminary actions to create the encapsulation matrix before adding biomaterials, the process avoids complex post-encapsulation purification steps.
4Ease of manufacture
If colloidal precursors such as sodium or potassium silicate are used, then the silica matrix can be formed, but the sodium or potassium ions must be removed
Solution Approach 1:
The patent employs commercial colloidal silica products that are designed for direct use in encapsulation applications. These preprocessed materials have already had harmful ions removed or neutralized during manufacturing, allowing direct use without additional purification steps.
Solution Approach 2:
The patent controls the pH and ionic composition parameters during silica matrix formation to prevent accumulation of harmful sodium or potassium ions. By adjusting these parameters, the process achieves effective encapsulation without requiring subsequent ion removal steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The silica-matrix encapsulation method effectively maintains the catalytic activity of biomaterials, enabling their practical application in biotechnology and medicine by preventing denaturation and aggregation, and allowing for efficient degradation of contaminants like atrazine in water and fracking water.
Implementation Method 1
a reactive silicon compound... when the biomaterial is encapsulated in the silica-matrix
Implementation Method 2
when the biomaterial is encapsulated in the silica-matrix
Implementation Method 3
silica-matrix encapsulation methods... preventing denaturation and aggregation
Implementation Method 4
nanoporous or macroporous structures... allowing for their use in extended periods
Data Source
AI summary
The present invention relates to compositions for encapsulation of biomaterials in a silica-matrix. The present invention includes a composition for formation of a silica-matrix encapsulated biomaterial. The composition includes a reactive silicon compound and a biomaterial with a catalytic activity. When encapsulated in the silica-matrix, the biomaterial at least partially retains its catalytic activity. The present invention also relates to methods of making silica-matrix encapsulated biomaterials, and to methods of using silica-matrix encapsulated biomaterials, including methods of treating water or gas using the silica-matrix encapsulated biomaterials.